Hodgkin's lymphoma: current treatment strategies and novel approaches. - Wikidata - awgldk - TriplyDB

Hodgkin's lymphoma: current treatment strategies and novel approaches.

Hodgkin's lymphoma: current treatment strategies and novel approaches.

http://www.wikidata.org/entity/Q37810114

about

Mocetinostat for relapsed classical Hodgkin's lymphoma: an open-label, single-arm, phase 2 trial.RECRUIT-TandAbs: harnessing the immune system to kill cancer cells.Rescue of impaired NK cell activity in hodgkin lymphoma with bispecific antibodies in vitro and in patients.Baseline serum TARC levels predict therapy outcome in patients with Hodgkin lymphoma.

P2860

Q37296330-966C125B-DCC5-45FF-B67C-EB1AB5C1F83A Q38024123-BA668A81-BD6E-4719-9E54-7F6A112A2C21 Q39185522-F8468197-63A0-4BB0-90FB-9F84C92E963F Q44757616-36D7A8E8-E948-49C4-9453-ADE2FCE04BFD

P2860

Hodgkin's lymphoma: current treatment strategies and novel approaches.

http://www.wikidata.org/entity/Q37810114

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on October 2008

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Hodgkin's lymphoma: current treatment strategies and novel approaches.

@en

Hodgkin's lymphoma: current treatment strategies and novel approaches.

@nl

type

label

Hodgkin's lymphoma: current treatment strategies and novel approaches.

@en

Hodgkin's lymphoma: current treatment strategies and novel approaches.

@nl

prefLabel

Hodgkin's lymphoma: current treatment strategies and novel approaches.

@en

Hodgkin's lymphoma: current treatment strategies and novel approaches.

@nl

P1433

Q37810114-6EFAAD3E-5809-4F11-BE84-00BEA3B9F2AF

P1476

Q37810114-01E217F3-CA86-499A-BA82-A342DA0EE5BF

P2093

Q37810114-08ECD602-BD98-4E5C-9614-CA867ABD4839

Q37810114-455C8429-6E1A-44AB-BCC8-B08668A281BC

Q37810114-62F2A676-2A59-4485-A021-18EA42F239CF

Q37810114-9A2C2140-EFE1-4CFC-8D08-7C6B9155167D

Q37810114-B5397747-A1AE-4D9C-9E5D-21E2D621FE94

P2860

Q37810114-0A18436A-17FB-416D-8002-C7EE44DD9C86

Q37810114-0BBCFC78-A97C-45A2-BCA5-DC260DC68C67

Q37810114-0E6084D9-B4AA-425E-84CB-0A717E933031

Q37810114-11EEC16B-C6ED-422C-967E-3B6D58652CD1

Q37810114-16397DCE-2C0B-4D1F-9993-DEF1DA25B51A

Q37810114-16EA1BD9-EAC8-4EBE-A5C0-4AA2C6CDA136

Q37810114-1C576BCE-1D04-48D7-818A-17063C493970

Q37810114-21000A18-69C0-45D2-AE7E-F748039D1A45

Q37810114-24013324-A125-492E-AABA-B3A47D78A0B6

Q37810114-2B1C8A15-8789-483E-B0FB-137A74592D00

P304

Q37810114-E879A590-E1AB-4570-B3C9-404E342BE1B2

P31

Q37810114-F02D8C1C-37D1-43DD-AAEC-C857BE25A4B9

P356

Q37810114-68DFC4DF-CE80-4497-A473-6D55540A8086

P433

Q37810114-36EBA206-7E16-43AC-9AFA-5960543722F7

P478

Q37810114-1CECC3B4-3C9F-4F5B-BD93-FE69FC624232

P577

Q37810114-22CE3DDA-2FA6-4450-804F-9C108EEEAAA3

P698

Q37810114-E6893BFC-498E-43A4-8BA1-43BB7A2E9409

P356

17474086.1.1.63

P1433

Expert Review of Hematology

P1476

Hodgkin's lymphoma: current treatment strategies and novel approaches.

@en

P2093

Andreas Engert

http://www.w3.org/2001/XMLSchema#string

Dennis A Eichenauer

http://www.w3.org/2001/XMLSchema#string

German Hodgkin Study Group

http://www.w3.org/2001/XMLSchema#string

Michael Fuchs

http://www.w3.org/2001/XMLSchema#string

Peter Borchmann

http://www.w3.org/2001/XMLSchema#string

P2860

Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD

Combination chemotherapy of Hodgkin's disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP

ABVD versus modified stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advanced-stage Hodgkin's lymphoma: final results of a multicenter randomized trial by the Intergruppo Italiano Linfomi

A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model.

Time-intensified dexamethasone/cisplatin/cytarabine: an effective salvage therapy with low toxicity in patients with relapsed and refractory Hodgkin's disease.

Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin's lymphoma: results of the HD8 trial of the German Hodgkin's

Ifosfamide, gemcitabine, and vinorelbine: a new induction regimen for refractory and relapsed Hodgkin's lymphoma.

Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804.

Phase 2 study of gemcitabine in combination with rituximab in patients with recurrent or refractory Hodgkin lymphoma.

The MINE regimen as intensive salvage chemotherapy for relapsed and refractory Hodgkin's disease.

P304

63-73

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1586/17474086.1.1.63

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

1

http://www.w3.org/2001/XMLSchema#string

P577

2008-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21083007

http://www.w3.org/2001/XMLSchema#string